Targeting HDAC6 improves anti-CD47 immunotherapy

Targeting HDAC6 improves anti-CD47 immunotherapy

Abstract Background Cancer cells can overexpress CD47, an innate immune checkpoint that prevents phagocytosis upon interaction with signal regulatory protein alpha (SIRPα) expressed in macrophages and other myeloid cells. Several clinical trials have reported that CD47 blockade reduces tumor growth...

Full description

Bibliographic Details
Main Authors: Maria Gracia-Hernandez, Ashutosh S. Yende, Nithya Gajendran, Zubaydah Alahmadi, Xintang Li, Zuleima Munoz, Karen Tan, Satish Noonepalle, Maho Shibata, Alejandro Villagra
Format: Article
Language:English
Published: BMC 2024-02-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
Histone deacetylases
CD47
Melanoma
Nexturastat A
Phagocytosis
Macrophages
Online Access:https://doi.org/10.1186/s13046-024-02982-4

Internet

https://doi.org/10.1186/s13046-024-02982-4

Similar Items